Allarity Therapeutics appoints Graff President, Iglesias CMO, Høiland Advisor to advance stenoparib

Allarity Therapeutics, Inc.

Jeremy Graff, Ph.D., named President & CDO; base salary $475K, RSUs $250K, signing bonus $75K.
Jose Iglesias, M.D., appointed Consultant CMO; led Phase III Abraxane development at Celgene.
Jesper Høiland, former President of Novo Nordisk U.S., joins as Strategic Advisor for commercial strategy.
Appointments target accelerating stenoparib, a dual PARP/Tankyrase inhibitor, for advanced ovarian cancer.
Graff previously consulted for Allarity since Dec 2023; brings 25+ years pharma experience including 17 at Eli Lilly.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeremy R. Graff

President and Chief Development Officer

ALLR · Allarity Therapeutics, Inc.

Effective: 2024-09-30
Filed: October 4, 2024, 7:59 PM ET

On October 3, 2024, Allarity Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy R. Graff, as the President and Chief Development Officer of the Company effective as of September 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeremy R. Graff was appointed as President and Chief Development Officer at Allarity Therapeutics, Inc..

Action: appointed
Role: President and Chief Development Officer

Exact text from the filing

On October 3, 2024, Allarity Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy R. Graff, as the President and Chief Development Officer of the Company effective as of September 30, 2024.

View on SEC.gov

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-030661

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.